1 treatment center
No centers match
Try a different search term
1 SAMHSA-listed treatment center in Matawan, New Jersey. Free, confidential help available 24/7 — most callers reach a licensed counselor in under 60 seconds.
Try a different search term
Free, confidential assistance matching you with the right program in Matawan.
Matawan, New Jersey has 1 SAMHSA-verified addiction treatment center offering 1 dual diagnosis, 1 outpatient. Each facility listed here is verified through the Substance Abuse and Mental Health Services Administration (SAMHSA) and provides evidence-based treatment approaches.
Outpatient programs allow Matawan residents to receive treatment while maintaining their daily responsibilities. Sessions are typically scheduled 3-5 days per week, making it possible to continue working or attending school.
Treatment centers in Matawan accept most major insurance plans including Medicaid, Medicare, Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare. Many facilities also offer sliding scale fees and payment plans. Call (319) 271-2077 to verify your coverage before admission.
Medicaid coverage for addiction treatment in Matawan depends on New Jersey's Medicaid program structure, expansion status, and any 1115 waivers in effect. The federal IMD Exclusion historically limited Medicaid coverage of large residential facilities; many states have obtained 1115 waivers expanding this coverage. Patients with Medicaid in New Jersey should contact their managed-care plan or the state Medicaid office to identify in-network addiction-treatment providers — many residential facilities accept Medicaid even when their primary patient mix is commercial.
Same-day or rapid admission to Matawan programs is most often possible at facilities with rolling intake capacity, particularly during weekday business hours. Weekend admissions are increasingly common but require advance arrangement. Emergency department presentation with active overdose or severe withdrawal sometimes serves as a bridge to Matawan treatment entry — hospital case managers can coordinate transfer to residential treatment directly from ED, particularly for patients with insurance that covers acute stabilization plus subsequent residential.
The first 90 days post-discharge are the highest-relapse-risk window for Matawan patients leaving residential treatment — multiple studies place 60-70% of relapses within this window. Structured continuity matters: same-team outpatient continuity, scheduled check-ins, structured-day expectations, and mutual-support engagement reduce 90-day relapse risk substantially compared to discharge-and-good-luck approaches. Programs that build this continuity into their model report measurably better outcomes than those treating discharge as the program endpoint.
ASAM levels of care available to Matawan residents range across the standard continuum: Level 1 outpatient counseling (less than 9 hours/week of structured programming), Level 2.1 intensive outpatient (9+ hours/week), Level 2.5 partial hospitalization (20+ hours/week), Level 3.1 clinically managed low-intensity residential, Level 3.5 medium-intensity residential, Level 3.7 medically monitored intensive inpatient, and Level 4 medically managed intensive inpatient (typically hospital-based detox for the most severe withdrawal presentations). Movement between levels follows clinical criteria, not calendar dates — patients step up when current intensity proves insufficient and step down as they stabilize.
Pregnant women in Matawan with active substance use should not stop opioid use abruptly if dependent — withdrawal during pregnancy carries fetal risk including preterm labor and stillbirth. Evidence-based care is buprenorphine or methadone maintenance (NOT detox), continued through pregnancy and postpartum. New Jersey maternal-fetal medicine specialists, OB-GYNs trained in addiction medicine, and SAMHSA's Center of Excellence for Pregnant and Postpartum Women with Opioid Use Disorder provide specialized care pathways for this population.
The addiction-treatment landscape in Matawan, New Jersey, reflects the broader epidemiology of substance use in the region: alcohol use disorder remains the most prevalent diagnosis at treatment intake nationally, opioid use disorder presents the highest overdose mortality, stimulant use disorder is increasingly common (cocaine and methamphetamine), and polysubstance use is the rule rather than the exception. Matawan providers structure programs to address this diversity — most treat the full range of substance-use disorders within an integrated clinical framework rather than maintaining substance-specific tracks.
Bipolar disorder requires specific clinical management in Matawan addiction-treatment settings: medication stabilization typically precedes deeper psychotherapy work, manic-phase substance use must be distinguished from continued substance use during depressive phases, and treatment planning accommodates the mood-cycling nature of the condition. Patients with bipolar disorder benefit from longer treatment episodes and more intensive aftercare than typical residential patients — relapse risk runs higher and clinical stabilization takes longer.